# Jacques Cadranel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jacques-cadranel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,075 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 63 |
| i10-index | 167 |
| Last Known Institution | Sorbonne Université |
| OpenAlex ID | https://openalex.org/A5114348469 |
| ORCID iD | 0000-0003-2446-2923 |
| Works | 476 |

## Researcher papers

- [Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures](https://scholariq.org/papers/long-term-survival-for-patients-with-non-small-cell-lung-cancer-with/)
- [Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial](https://scholariq.org/papers/afatinib-versus-placebo-for-patients-with-advanced-metastatic-non-small-cell/)
- [Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia](https://scholariq.org/papers/effect-of-tocilizumab-vs-usual-care-in-adults-hospitalized-with-covid-19-and/)
- [Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19](https://scholariq.org/papers/association-between-administration-of-il-6-antagonists-and-mortality-among/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial](https://scholariq.org/papers/nivolumab-or-nivolumab-plus-ipilimumab-in-patients-with-relapsed-malignant/)
- [Primary pulmonary lymphoma](https://scholariq.org/papers/primary-pulmonary-lymphoma/)
- [Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer](https://scholariq.org/papers/immune-checkpoint-inhibitor-related-myositis-and-myocarditis-in-patients-with/)
- [Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network](https://scholariq.org/papers/rare-egfr-exon-18-and-exon-20-mutations-in-non-small-cell-lung-cancer-on-10-117/)
- [Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial](https://scholariq.org/papers/effect-of-anakinra-versus-usual-care-in-adults-in-hospital-with-covid-19-and/)
- [Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study](https://scholariq.org/papers/resistance-mechanisms-to-osimertinib-in-egfr-mutated-advanced-non-small-cell/)
- [Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers](https://scholariq.org/papers/detection-of-acquired-tert-amplification-in-addition-to-predisposing-p53-and-rb/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Sorbonne Université](https://scholariq.org/institutions/sorbonne-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.